Roderick Tung

So very proud of what WE are building in the 5th largest city in the US. This is the Banner – University Medicine Phoenix Heart Institute. youtu.be/bhGVyxU7BVQ?si…

Welcoming Dr. Anupama Joseph to the Valley of the Sun!🌄 We are excited to have her join our non-invasive and imaging section, bringing her experience from UWisconsin – where she won Cardiovascular Medicine Fellowship Outstanding Educator Award and led focused clinics in health equity for ASVCD prevention.

@bogdienache @drjohnm In one of the original Braunwald editions, they discuss this very concept and propose "infarct cardiomyopathy"

@DrRoderickTung @drjohnm I think whoever called it “ischemic” VT is partially at fault here.

That’s another thing that drives me bananas: sending pts w AF for coronary angiography. Dumb. Dumb. Double dumb.

@JACCJournals @DrRoderickTung @davidgzcasal @DamianSanc1955 @TomasDatino @AdolfoFontenla The Septopulmonary Bundle Revisited as an Integrated 3-Dimensional Myocardial Region With Implications for Atrial Ablation @davidgzcasal @DrRoderickTung @DamianSanc1955 @JACCJournals #JACCCR @cardiac_anatomy sciencedirect.com/science/articl…

Welcoming @AnumAsifBukhari to our faculty! Dr. Asif will be joining our Interventional Cardiology section led by @psorajja after Structural Cardiology Fellowship at Brown University. She completed a Clinical Research Fellowship at Cedars-Sinai with clinical interests in women's heart care and transcatheter valve intervention.

We kick off our 4th annual Valley of the Sun Heart Symposium tomorrow! For anyone interested in an ECG primer, my mentor Dr. @KennethEllenbo1 will be here to kick things off with me with an intensive ECG review for all learners (med students, residents, fellows, APP, MD). See you all at 2pm!

Great talk! @DrRoderickTung @BannerHealth @uarizona

Welcoming Dr @MargaridaPujol officially as Scientist @uazmedphx!!

Over the moon to have THE best as my chief @uazphxcards @DrRoderickTung UA ❤️ team 🌵🏜️🐦‍🔥 youtube.com/watch?v=bhGVyx…

GLP-1 use cuts atrial fibrillation risk regardless of weight loss healio.com/news/cardiolog…

Nice conversation about the start of the ASC era at academic medical centers like Johns Hopkins and Banner – University Medicine. #HRS2026

Heart Rhythm TV is signing off from Chicago! This photo says it all. It's been an honor bringing you every moment. We have SO much content still on the way that we cannot wait for you to see. Stay tuned, and follow Heart Rhythm TV for more ➡️ bit.ly/4cDyK6d The best is yet to come. 🙌 @HRSonline @DanielAlyeshmer, @MehakDhande, @drsuneet, @jczerpa, Jeanne du Fay de Lavallaz, @HeartRhythmNP, @Nashwa_Salem_, @np_varghese, @OliverMonfredi, @AZ_EP_DOC, @melchami99

Open access books can be downloaded using this QR code. Content also appears weekly in @JACCJournals Thank you to @HRSonline for making this a special annual component of HRS for all EP’s.

We are so excited to announce that Dr. Paul Mahoney will be joining our growing team as Director of Transcatheter Valve Therapy. Welcoming you and your expertise, partner! @PaulMahoneyMD Phoenix is Rising. 🐦‍🔥🌵

More than 10 years ago Oussama and I started our journey of investigation, trying to the define the optimal first treatment for patients with atrial fibrillation.  Separately we pursed randomised studies in populations with treatment-naive paroxysmal AF.  Five years ago we presented our RCTs in the paroxysmal AF population, which ended up sitting side by side in the same issue of the New England Journal of Medicine.  nejm.org/doi/full/10.10… nejm.org/doi/full/10.10… Since then we have been working together to examine the same question of optimal initial therapy, but instead looking at patients with more advanced forms of atrial fibrillation.  Today Oussama presented the results of the AVANT-GUARD study, which definitively demonstrated the value of initial catheter ablation in the treatment naive persistent AF population. Like EARLY-AF, AVAT GUARD used implantable cardiac monitors to evaluate arrhythmia endpoints   Like EARLY-AF - initial catheter ablation reduced recurrences in AVANT GUARD by about 50%, which was about 25% in absolute terms. To put this another way, only 4 patients need to be treated with ablation to prevent a recurrence of arrhythmia.  However, binary recurrence doesn’t tell the whole story. Because we had loop recorders we were able to assess the time spent in AF (or AF burden). In this regard significantly more patients had none or negligible burden after ablation (<0.1%), with significantly more AAD treated patients having a very high burden (>5%). This is important as AF burden is associated with clinical outcomes such as hospitalisation. In terms of risk - the rates of any adverse event or serious adverse event were comparable between randomised arms. Highlighting that persistent AF patients with high CHADS-VASc score are high risk irrespective of treatment provided. This is important as we reflect on treatment options as part of shared decision-making. Congratulations to Oussama for the presentation and leadership, to the co-investigators and study sites for their participation and dedication, and a huge thank you to the Boston Scientific team for their support and commitment to advancing science.  To end, I want to acknowledge and thank Oussama for this shared journey, I’m grateful for our collaboration and friendship, and look forward to what we will do next.

Awesome day in the classroom! #HRS2026

Congrats to all of the lifelong learners for surviving a 3 hour anatomy course! Incredible outpouring that inspires us further. 🙏 @shivkumarmd @BIOTRONIK_US

@HRSonline @HeartRhythmTV @experienceHRX #AHPs are the Heart ♥️ of HRS! @DrRoderickTung and band are the “soul” of HRS! So much fun! #Collegiality #Music @SanaAlkhatib9 @KTamirisaMD @netta_doc @JagSinghMD @leftbundle @AndreaRussoEP @AndrewKrahnMD